MiNK Therapeutics, Inc.
Moat Score — MiNK Therapeutics, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | MiNK holds 4 issued U.S. and 5 issued foreign patents plus 30+ pending applications around its off-the-shelf iNKT cell platform, and its closed-system manufacturing process yields >99% pure iNKT cells, a real but still unproven-at-scale technical edge. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | MiNK's shared-services arrangement with Agenus keeps its own headcount to just 15 employees, but this reflects financial necessity rather than a structural cost advantage over better-capitalized cell-therapy competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved products or revenue, MiNK has no demonstrated pricing power; any future pricing will depend entirely on clinical data not yet in hand. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Cell therapy manufacturing and clinical development exhibit no network effect; neither patients nor physicians create added value for other users of the platform. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no commercial product, there are no real switching costs yet; any future stickiness would depend on physician and payer adoption patterns that cannot be assessed pre-approval. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The off-the-shelf, allogeneic manufacturing model is designed to be more scalable than per-patient autologous cell therapy, but MiNK's single Lexington, MA facility and small balance sheet mean this scale advantage is largely theoretical until clinical and commercial validation. |